Lawrence Otto Klein - 01 Sep 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ORKA
Reported as of: 01 Sep 2026
Net transaction value: -$6,887,484
SEC form: 4
Accepted by SEC: 01 Sep 2026, 18:35:04 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein

Key filing fact

Lawrence Otto Klein filed Form 4 for Oruka Therapeutics, Inc. (ORKA) on 01 Sep 2026.

Key facts

This page summarizes Lawrence Otto Klein's Form 4 filing for Oruka Therapeutics, Inc. (ORKA).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Sep 2026, 18:35.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: -$6,887,484.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001762583 Primary reporting owner

Klein Lawrence Otto

Relationship: Chief Executive Officer, Director
Address: C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK
Signature: /s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein
Signature date: 01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORKA transaction

Common Stock

Options Exercise

Transaction value
Shares: +75,000
Change %: +8.1%
Price: $7.80^*
Shares after: 1,000,580
Date: 01 Sep 2026
Ownership: Direct

ORKA transaction

Common Stock

Sale

Transaction value: $599,556
Shares: -6,604
Change %: -0.66%
Price: $90.79
Shares after: 993,976
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2

ORKA transaction

Common Stock

Sale

Transaction value: $5,844,237
Shares: -63,596
Change %: -6.4%
Price: $91.90
Shares after: 930,380
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F3

ORKA transaction

Common Stock

Sale

Transaction value: $443,691
Shares: -4,800
Change %: -0.52%
Price: $92.44
Shares after: 925,580
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORKA transaction Derivative

Employee Warrant (right to buy)

Options Exercise

Transaction value
Shares: -75,000
Change %: -4.6%
Price: $0.000000^*
Shares after: 1,553,513
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $7.80
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $91.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.28 to $92.27, inclusive.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.31 to $92.59, inclusive.

Footnote F5

The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.